GlassScriptPhysician profile
Larissa Luu
NPI 1750940714
$4,648.61
in general payments reported to CMS, 2019-2025
32 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $419 · 2023: $1,667 · 2024: $2,157 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,229.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.93 | 2022-2025 | |
| Novo Nordisk INC | $654.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $478.34 | 2023-2025 | |
| Lilly USA, LLC | $324.06 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $309.19 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $252.03 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bausch Health US, LLC | $204.50 | 2022-2025 | Aplenzin, Wellbutrin |
| Bayer Healthcare Pharmaceuticals INC. | $177.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.54 | 2022-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $145.08 | 2023-2025 | Ajovy |
| Exact Sciences Corporation | $138.92 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $132.27 | 2023-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.27 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.48 | 2022-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $107.24 | 2024 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $59.23 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $55.88 | 2023-2024 | Accrufer |
| Idorsia Pharmaceuticals US INC | $54.30 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $51.12 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Almatica Pharma LLC | $48.91 | 2024-2025 | Teriparatide, Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $46.80 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $40.94 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $38.84 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $23.54 | 2023 | Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $23.47 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $22.91 | 2022 | |
| Esperion Therapeutics, INC. | $20.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.85 | 2025 | Belbuca |
| Paratek Pharmaceuticals, INC. | $18.33 | 2022 | |
| Eisai INC. | $17.86 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.76 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $15.64 | 2023 | Contrave, Nexlizet, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.